• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Technology

Nanoparticles Reprogram Ascitic Macrophages into CAR Cells in Rodent Models

by
November 7, 2026
in Technology
Reading Time: 4 mins read
0
Nanoparticles Reprogram Ascitic Macrophages into CAR Cells in Rodent Models

Nanoparticles Reprogram Ascitic Macrophages into CAR Cells in Rodent Models

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have developed lipid nanoparticles encapsulating messenger RNA that reprogram immunosuppressive tumour-associated macrophages in malignant ascites into chimeric antigen receptor macrophages targeting Claudin18.2-positive tumour cells in rodent models and patient-derived samples. Single-cell analysis of patient-derived peritoneal metastasis and malignant tumour ascites revealed that TREM2-positive tumour-associated macrophages are enriched by approximately 90 percent, driving CD8-positive T cell dysfunction and tumour growth.

The engineered lipid nanoparticles incorporate a TREM2 ligand designed to enhance selective targeting toward TREM2-expressing macrophages within the ascites microenvironment. Experimental evaluation confirmed that these mRNA-loaded formulations preferentially accumulate in TREM2-positive tumour-associated macrophages across both human and murine ascites models.

A piperazine-containing phosphoramide ionizable lipid within the nanoparticles works synergistically with the TREM2 ligand to inhibit ligand dissociation. This interaction promotes TREM2 internalization and degradation through lysosomal and autophagosomal pathways, downregulating TREM2 and shifting macrophages toward a pro-inflammatory antitumour state.

The degradation of TREM2 inhibits downstream AKT signalling and reprograms the tumour-associated macrophages to counteract local immune suppression. This phenotypic shift enhances progenitor exhausted and effector memory CD8-positive T cell responses while altering the peritoneal metastasis transcriptome across both malignant ascites and solid tumours.

In murine studies, intraperitoneal injection of PL41-PG lipid nanoparticles and CAR macrophages stimulated adaptive immune responses and prolonged survival in MC38-hCLDN18.2 ascites models. When combined with standard programmed cell death protein 1 blockade, early-stage therapy in ID8 tumour models suppressed tumour growth and extended mouse survival.

Ex vivo evaluation using clinical donor ascites demonstrated that treatment with the nanoparticles reversed immunosuppressive macrophage phenotypes, enhanced T cell activation, and reduced Claudin18.2-positive tumour cells. These matching immunological responses in human ascites specimens highlight the translational potential of the platform for peritoneal metastasis immunotherapy, with current therapeutic outcomes observed in rodent models.

The study focuses on the therapeutic challenges presented by advanced gastrointestinal cancers, in which peritoneal metastasis and malignant tumour ascites frequently develop. In these advanced clinical settings, patient prognosis remains poor, and existing therapies typically offer limited therapeutic response. Investigating the cellular composition of this disease environment through single-cell analysis of patient-derived peritoneal metastasis and malignant tumour ascites specimens, the researchers identified an approximately 90 percent enrichment of TREM2-positive tumour-associated macrophages. These abundant macrophages play an active pathological role in disease progression by driving CD8-positive T cell dysfunction and accelerating tumour growth. Complementing the human single-cell observations, evaluation across both tumour-bearing humans and tumour-bearing mice confirmed that TREM2 overexpression is a consistent hallmark within malignant tumour ascites.

To address these pathological conditions, the researchers engineered lipid nanoparticles encapsulating messenger RNA to achieve direct in situ cell engineering within ascitic fluid. This strategy converts endogenous TREM2-positive tumour-associated macrophages into chimeric antigen receptor macrophages targeted against Claudin18.2-positive tumour ascites. The lipid nanoparticle architecture incorporates a specific TREM2 ligand designed to enhance selective delivery to and accumulation within TREM2-positive macrophages. Mechanistically, a piperazine-containing phosphoramide ionizable lipid within the formulation synergizes with the TREM2 ligand to prevent ligand dissociation from the receptor. This sustained interaction facilitates receptor internalization and routes TREM2 through both lysosomal and autophagosomal degradation pathways, resulting in receptor downregulation and promoting pro-inflammatory macrophage polarization toward an antitumour phenotype.

Downstream molecular analyses showed that degradation of the TREM2 receptor suppresses intracellular AKT signalling within the reprogrammed macrophages. This inhibition reduces regional immunosuppression across both malignant tumour ascites and solid tumour masses while inducing comprehensive alterations across the peritoneal metastasis transcriptome. Phenotypically, the reprogrammed chimeric antigen receptor macrophages stimulate host adaptive immunity, specifically augmenting both progenitor exhausted and effector memory CD8-positive T cell responses. By revitalizing these distinct CD8-positive T lymphocyte populations, the in situ engineering approach shifts the peritoneal metastatic microenvironment from a suppressed state toward active antitumour immunity that facilitates the elimination of malignant cells.

Therapeutic efficacy was systematically assessed across distinct rodent models and patient-derived materials. In preclinical mouse studies, intraperitoneal injection of the PL41-PG lipid nanoparticles and generated PL41-PG chimeric antigen receptor macrophages activated adaptive immunity and significantly prolonged host survival in MC38-hCLDN18.2 ascites models. When evaluated as an early-stage combination therapy in ID8 tumour models, co-administration of the engineered PL41-PG CAR macrophages with standard anti-PD-1 checkpoint antibodies suppressed tumour progression and extended overall survival in mice. Parallel experiments conducted with human donor ascites demonstrated that treatment with PL41-PG lipid nanoparticles and CAR cells reversed immunosuppressive macrophage states, enhanced human T cell activation, and diminished Claudin18.2-positive tumour cells. These matching immunological responses support the translational potential of this platform for peritoneal metastasis immunotherapy, while confirming that reported survival gains currently remain established in murine models.

Subject of Research: In situ CAR macrophage reprogramming for malignant ascites immunotherapy

Article Title: In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

Article References: Li, Y., Yang, T., Zhang, X., Peng, R., Gong, J., Zhang, Z., Ma, B., Hou, Y., Liu, Y., Chen, K., Bai, Q., Fang, Y., Cao, C., Hao, J., Sun, Z., Jiang, Z., Dong, M., Wei, C., Li, Z., … Miao, L. (2026). In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites. Nature Materials. https://doi.org/10.1038/s41563-026-02769-2

Image Credits: AI Generated

DOI: 10.1038/s41563-026-02769-2

Keywords: Lipid nanoparticles, Malignant ascites, CAR macrophages, TREM2 degradation, Claudin18.2, Cancer immunotherapy, Peritoneal metastasis, PD-1 blockade, situ, engineering, nanoparticle-mediated, TREM2

News Source: Nathaniel Bowman. (November 7, 2026). Nanoparticles Reprogram Ascitic Macrophages into CAR Cells in Rodent Models. Scienmag.

Tags: Cancer immunotherapyCAR macrophagesClaudin18.2engineeringlipid nanoparticlesmalignant ascitesnanoparticle-mediatedPD-1 blockadeperitoneal metastasissituTREM2TREM2 degradation
Share12Tweet7Share2ShareShareShare1

Related Posts

TCAD Simulations Identify Efficiency Gains for Sustainable CZTS Solar Cells

TCAD Simulations Identify Efficiency Gains for Sustainable CZTS Solar Cells

November 17, 2026
Topological Twists Defined for Supersymmetric Field Theories With Open Supercharge Algebras

Topological Twists Defined for Supersymmetric Field Theories With Open Supercharge Algebras

November 17, 2026

Blended Iron Ore Tailings Can Fully Replace Natural Sand in Concrete

November 17, 2026

Selective Super-Twisting Controller Achieves Centimetre-Level Tracking in PVTOL Aircraft Simulations

November 17, 2026

POPULAR NEWS

  • Structured IDEA Expert Elicitation Framework Enhances Design of Rare Disease Trials

    Structured IDEA Expert Elicitation Framework Enhances Design of Rare Disease Trials

    29 shares
    Share 12 Tweet 7
  • Syndesmotic Fixation Speeds Early Ankle Recovery but Matches Non-Fixation at Two Years

    29 shares
    Share 12 Tweet 7
  • German Nationwide Survey Identifies Workplace Bullying Patterns Across Industries and Age Groups

    29 shares
    Share 12 Tweet 7
  • TCAD Simulations Identify Efficiency Gains for Sustainable CZTS Solar Cells

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Structured IDEA Expert Elicitation Framework Enhances Design of Rare Disease Trials

Syndesmotic Fixation Speeds Early Ankle Recovery but Matches Non-Fixation at Two Years

German Nationwide Survey Identifies Workplace Bullying Patterns Across Industries and Age Groups

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.